Global threat of carbapenem-resistant gram-negative bacteria
Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …
Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane
A Sabnis, KLH Hagart, A Klöckner, M Becce, LE Evans… - elife, 2021 - elifesciences.org
Colistin is an antibiotic of last resort, but has poor efficacy and resistance is a growing
problem. Whilst it is well established that colistin disrupts the bacterial outer membrane (OM) …
problem. Whilst it is well established that colistin disrupts the bacterial outer membrane (OM) …
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
Acinetobacter baumannii: evolution of antimicrobial resistance—treatment options
The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
JA Viehman, MH Nguyen, Y Doi - Drugs, 2014 - Springer
Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide.
Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents …
Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents …
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse …
Objectives This study investigated the exposure–response relationships between unbound
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
Inhaled formulations and pulmonary drug delivery systems for respiratory infections
Respiratory infections represent a major global health problem. They are often treated by
parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose …
parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose …
Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia
SS Jean, YC Chang, WC Lin, WS Lee… - Journal of clinical …, 2020 - mdpi.com
Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR)
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-
line option for the treatment of infections caused by extensively drug-resistant Gram …
line option for the treatment of infections caused by extensively drug-resistant Gram …